Your browser doesn't support javascript.
loading
Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study.
Anastasopoulou, Stavroula; Swann, Gemma; Andres-Jensen, Liv; Attarbaschi, Andishe; Barzilai-Birenboim, Shlomit; Erdelyi, Daniel J; Escherich, Gabriele; Hamadeh, Lina; Harila, Arja; Lopez-Lopez, Elixabet; McGowan, Sheena; Möricke, Anja; Putti, Caterina; Sagi, Judit C; Schmiegelow, Kjeld; Ullrich, Nicole J; van der Sluis, Inge M; Wahid, Qurat-Ul-Ain; Winick, Naomi; Sramkova, Lucie; Zalcberg, Yair; Zapotocka, Ester; Bhojwani, Deepa; Halsey, Christina.
Affiliation
  • Anastasopoulou S; Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
  • Swann G; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Andres-Jensen L; Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland.
  • Attarbaschi A; Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Barzilai-Birenboim S; Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
  • Erdelyi DJ; St. Anna Children's Cancer Research Institute, Vienna, Austria.
  • Escherich G; Department of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Hamadeh L; Department of Paediatrics, Semmelweis University, Budapest, Hungary.
  • Harila A; University Medical Centre Hamburg-Eppendorf, Clinic of Paediatric Haematology and Oncology, Hamburg, Germany.
  • Lopez-Lopez E; Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • McGowan S; Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
  • Möricke A; Department of Biochemistry and Molecular Biology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain.
  • Putti C; Pediatric Oncology Group, Biobizkaia Health Research Institute, Barakaldo, Spain.
  • Sagi JC; Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland.
  • Schmiegelow K; Department of Pediatrics I, Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian Albrechts University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.
  • Ullrich NJ; Department of Woman and Child Health, Clinic of Pediatric Haematology-Oncology, University of Padova, Padova, Italy.
  • van der Sluis IM; Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary.
  • Wahid QU; Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary.
  • Winick N; Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Sramkova L; Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Zalcberg Y; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Zapotocka E; Princess Maxima Center for Pedatric Oncology, Utrecht, the Netherlands.
  • Bhojwani D; Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland.
  • Halsey C; University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Br J Haematol ; 2024 Jun 25.
Article in En | MEDLINE | ID: mdl-38924051
ABSTRACT
Steroids are a mainstay in the treatment of acute lymphoblastic leukaemia (ALL) in children and adolescents; however, their use can cause clinically significant steroid-related neuropsychiatric symptoms (SRNS). As current knowledge on SRNS during ALL treatment is limited, we mapped the phenotypes, occurrence and treatment strategies using a database created by the international Ponte di Legno Neurotoxicity Working Group including data on toxicity in the central nervous system (CNS) in patients treated with frontline ALL protocols between 2000 and 2017. Ninety-four of 1813 patients in the CNS toxicity database (5.2%) experienced clinically significant SRNS with two peaks one during induction and one during intensification phase. Dexamethasone was implicated in 86% of SRNS episodes. The most common symptoms were psychosis (52%), agitation (44%) and aggression (31%). Pharmacological treatment, mainly antipsychotics and benzodiazepines, was given to 87% of patients while 38% were hospitalised due to their symptoms. Recurrence of symptoms was reported in 29% of patients and two previously healthy patients required ongoing pharmacological treatment at the last follow up. Awareness of SRNS during ALL treatment and recommendation on treatment strategies merit further studies and consensus.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Br J Haematol Year: 2024 Document type: Article Affiliation country: Sweden

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Br J Haematol Year: 2024 Document type: Article Affiliation country: Sweden
...